Skip to Content

Verastem Inc

Rating as of

Company Profile

Business Description

Verastem Inc is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Contact
117 Kendrick Street, Suite 500
Needham, MA, 02494
T +1 781 292-4200
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Distressed
Employees 135